Bellerophon Therapeutics Shares Owned By Institutions vs. EBITDA
| BLPHDelisted Stock | USD 0.71 0.01 1.43% |
For Bellerophon Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bellerophon Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bellerophon Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bellerophon Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bellerophon Therapeutics over time as well as its relative position and ranking within its peers.
Bellerophon |
Bellerophon Therapeutics EBITDA vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Bellerophon Therapeutics's current stock value. Our valuation model uses many indicators to compare Bellerophon Therapeutics value to that of its competitors to determine the firm's financial worth. Bellerophon Therapeutics is rated third in shares owned by institutions category among its peers. It is rated below average in ebitda category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bellerophon Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bellerophon Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bellerophon EBITDA vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Bellerophon Therapeutics |
| = | 45.08 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Bellerophon Therapeutics |
| = | (22.39 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Bellerophon EBITDA Comparison
Bellerophon Therapeutics is currently under evaluation in ebitda category among its peers.
Bellerophon Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Bellerophon Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bellerophon Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Bellerophon Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Bellerophon Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people.
Bellerophon Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Bellerophon Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bellerophon Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bellerophon Therapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Bellerophon Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Positions Ratings Now
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Use Investing Themes to Complement your Bellerophon Therapeutics position
In addition to having Bellerophon Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run FinTech Thematic Idea Now
FinTech
High long term potential financial entities that are ranging from payment processing, investment management to commercial and investment banking. The FinTech theme has 81 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize FinTech Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Bellerophon Pink Sheet
If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |